KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) FCF Margin (2016 - 2025)

Historic FCF Margin for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to 8.6%.

  • Travere Therapeutics' FCF Margin rose 761800.0% to 8.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.48%, marking a year-over-year increase of 1173800.0%. This contributed to the annual value of 101.84% for FY2024, which is 1226300.0% up from last year.
  • As of Q3 2025, Travere Therapeutics' FCF Margin stood at 8.6%, which was up 761800.0% from 4.35% recorded in Q2 2025.
  • Travere Therapeutics' 5-year FCF Margin high stood at 57.66% for Q3 2021, and its period low was 327.8% during Q3 2022.
  • Over the past 5 years, Travere Therapeutics' median FCF Margin value was 74.52% (recorded in 2024), while the average stood at 123.63%.
  • In the last 5 years, Travere Therapeutics' FCF Margin crashed by -3854600bps in 2022 and then soared by 2360100bps in 2025.
  • Travere Therapeutics' FCF Margin (Quarter) stood at 55.91% in 2021, then crashed by -568bps to 261.54% in 2022, then surged by 45bps to 142.92% in 2023, then skyrocketed by 67bps to 47.76% in 2024, then surged by 118bps to 8.6% in 2025.
  • Its FCF Margin stands at 8.6% for Q3 2025, versus 4.35% for Q2 2025 and 51.62% for Q1 2025.